Liu Jiayou, Hu Jiyuan, Gao Xue, Liu Hongfang
Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing, China.
School of Traditional Chinese Medicine, Beijing University of Chinese Medicine, Beijing, China.
Int J Surg. 2025 Jul 1;111(7):4807-4811. doi: 10.1097/JS9.0000000000002479. Epub 2025 May 20.
Over the past two decades, a systematic elucidation of the overall trajectory and clinical translation of stem cell research in kidney diseases has been lacking. To address this gap, we conducted a bibliometric analysis and clinical trial search focusing on the period from 2005 to 2025, thereby mapping the global landscape of stem cell research in kidney diseases. Our results indicate a growing body of literature, accompanied by extensive international collaborations, with the United States and China leading in research output. In terms of research themes, mesenchymal stem cells continue to garner sustained attention for their reparative applications. Over the past decade, there has been a marked increase in studies on exosomes, extracellular vesicles, and kidney organoids. Nevertheless, clinical translation remains relatively delayed, suggesting that laboratory discoveries require additional time to reach bedside applications. This study provides a global perspective grounded in empirical data, helping to clarify critical frontiers and challenges.
在过去二十年中，一直缺乏对肾脏疾病干细胞研究的总体轨迹和临床转化的系统阐释。为了填补这一空白，我们进行了一项文献计量分析和临床试验搜索，重点关注2005年至2025年期间，从而描绘出肾脏疾病干细胞研究的全球格局。我们的结果表明，文献数量不断增加，同时伴随着广泛的国际合作，美国和中国在研究产出方面领先。在研究主题方面，间充质干细胞因其修复应用继续受到持续关注。在过去十年中，关于外泌体、细胞外囊泡和肾脏类器官的研究显著增加。然而，临床转化仍然相对滞后，这表明实验室发现需要更多时间才能应用于临床。本研究提供了基于实证数据的全球视角，有助于厘清关键前沿和挑战。
